Trials / Unknown
UnknownNCT04431791
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
A Single-center，Observational，Ambispective Cohort Study of Regorafenib Versus Fruquintinib in Metastatic Colorectal Cancer Patients Who Have Progressed After at Least Second Lines of Chemotherapies
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 268 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China. About 268 eligible metastatic colorectal cancer patients after second-line therapy will be assigned to receive either regorafenib or fruquintinib, based on decision of the gastrointestinal physician according the patients' condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib | oral regorafenib |
| DRUG | Fruquintinib | oral fruquintinib |
Timeline
- Start date
- 2020-05-25
- Primary completion
- 2021-08-01
- Completion
- 2022-02-01
- First posted
- 2020-06-16
- Last updated
- 2020-06-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04431791. Inclusion in this directory is not an endorsement.